<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160285</url>
  </required_header>
  <id_info>
    <org_study_id>KCGMHCTC-2019005</org_study_id>
    <secondary_id>CPRPG8J0011</secondary_id>
    <nct_id>NCT05160285</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma</brief_title>
  <official_title>The NEVOLUTION Study: An Open Label, Single-arm, Phase II Study of Neoadjuvant Nivolumab in Locally Advanced Upper Tract Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>YULISU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for&#xD;
      non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive&#xD;
      biomarkers of immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upper urinary tract urothelial carcinoma (UTUC) is a malignant tumor originated from the&#xD;
      epithelium of upper urinary tract (renal pelvis and ureter). The standard treatment of UTUC&#xD;
      is radical nephroureterectomy with ipsilateral bladder cuff excision. For locally advanced&#xD;
      disease, neoadjuvant chemotherapy or adjuvant chemotherapy with radiotherapy is also a&#xD;
      considerable treatment. In general, patients with UTUC are often diagnosed in a late stage&#xD;
      with a poor survival.&#xD;
&#xD;
      Nowadays, immune checkpoint inhibitor (ICI) emerged huge success in treatment of various type&#xD;
      of cancers, including metastatic urothelial carcinoma. Several anti-PD1 or PD-L1 agents&#xD;
      demonstrated an exciting response for metastatic urothelial carcinoma. The encouraging&#xD;
      success makes clinical trials moving forward to neoadjuvant setting. In the PURE-01 study,&#xD;
      patients with muscle-invasive bladder cancer received 3 cycles of neoadjuvant pembrolizumab&#xD;
      achieving 39.5% pathological complete response (pCR). It brought a brand-new hope for&#xD;
      organ-preservation treatment strategy. So far, neoadjuvant ICI has not been tested in&#xD;
      patients with UTUC, irrespective for treatment efficacy or safety analysis. More importantly,&#xD;
      there is still lack of reliable biomarkers to predict treatment response of ICI, which&#xD;
      definitely an unmet medical need in clinical practice.&#xD;
&#xD;
      Therefore, the investigators proposed a phase II, open-label study of neoadjuvant nivolumab&#xD;
      in locally advanced UTUC. Investigators believe that neoadjuvant nivolumab will achieve at&#xD;
      least similar pCR rate compared with neoadjuvant pembrolizumab in UCB patients. Furthermore,&#xD;
      investigators will conduct a comprehensive exploratory genomic analysis to identify the&#xD;
      potential candidate biomarkers to predict the response of nivolumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label, Single-arm, Phase II Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response rate (pCR)</measure>
    <time_frame>1 month post neoadjuvant nivolumab and surgery</time_frame>
    <description>determined by genitourologic pathologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse effect</measure>
    <time_frame>3 months during nivolumab treatment</time_frame>
    <description>determined by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complication</measure>
    <time_frame>1 month within surgery</time_frame>
    <description>determined by Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
    <description>determined by RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Milestone time points analysis of DFS6, DFS12, DFS 18 and median PFS by investigator assessment per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <description>Milestone time points analysis of OS6, OS12, OS18 and median OS by investigator assessment per RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Upper Urinary Tract Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant nivolumab treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 360mg intravenous adminstration every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 100 MG in 10 ML Injection</intervention_name>
    <description>If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.</description>
    <arm_group_label>Neoadjuvant nivolumab treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a histologically or clinically confirmed diagnosis of locally advanced (cT2-T4&#xD;
             and N0M0) urothelial carcinoma of the renal pelvis and/or ureter (UTUC). Pure&#xD;
             urothelial carcinoma or urothelial carcinoma mixed with other histological variant are&#xD;
             allowed, but urothelial carcinoma must be the predominant histology.&#xD;
&#xD;
          2. Have at least a measurable lesion based on RECIST 1.1 as determined by the local site&#xD;
             investigator/radiology assessment.&#xD;
&#xD;
          3. Voluntarily agree to participate by providing written informed consent/assent for the&#xD;
             trial.&#xD;
&#xD;
          4. Age (at the time of informed consent): 20 years and older&#xD;
&#xD;
          5. Have received no prior systemic chemotherapy for advanced urothelial carcinoma, with&#xD;
             the following exceptions:&#xD;
&#xD;
               1. Platinum-based chemotherapy for previous a history of ipsilateral UTUC or bladder&#xD;
                  cancer in purpose of neoadjuvant or adjuvant treatment with recurrence &gt; 6 months&#xD;
                  from completion of therapy is permitted.&#xD;
&#xD;
               2. Low-dose chemotherapy (e.g., low-dose cisplatin, cisplatin plus 5-FU, mitomycin&#xD;
                  plus 5-FU, or cisplatin plus paclitaxel) given concurrently with radiation to&#xD;
                  urothelial carcinoma of bladder is not considered systemic therapy.&#xD;
&#xD;
          6. Have willing to provide tissue for exploratory biomarker analysis from a newly&#xD;
             obtained core or excisional biopsy of a tumor lesion from the renal pelvis or ureter&#xD;
             tumor.&#xD;
&#xD;
          7. Have an ECOG PS of 0, 1, or 2.&#xD;
&#xD;
          8. Have adequate organ function as defined in Table 6. (All screening labs should be&#xD;
             performed within 3 weeks prior to treatment initiation.)&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative urine or serum&#xD;
             pregnancy test within 72 hours prior to receiving the first dose of trial medication.&#xD;
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required.&#xD;
&#xD;
         10. Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception as outlined in Section 7.5.2 - Contraception, for the course of the&#xD;
             trial through 5 months or more after the last dose of nivolumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Is currently participating and receiving study therapy or investigational agents.&#xD;
             Patients who withdraw of previous clinical trials should have a 4-weeks washout period&#xD;
             of investigational drug before participating this study.&#xD;
&#xD;
             2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to randomization.&#xD;
&#xD;
             3. Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years (i.e., with use of disease-modifying agents, corticosteroids, or&#xD;
             immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or&#xD;
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,&#xD;
             etc.) is not considered a form of systemic treatment.&#xD;
&#xD;
               1. Short-term (&lt;7 days) use of systemic corticosteroids is allowed when use is&#xD;
                  considered SOC.&#xD;
&#xD;
               2. Subjects with vitiligo, type I diabetes mellitus, hypothyroidism, or resolved&#xD;
                  childhood asthma/atopy would be an exception to this rule.&#xD;
&#xD;
               3. Subjects who require intermittent use of bronchodilators, inhaled steroids, or&#xD;
                  local steroid injections would not be excluded from the trial.&#xD;
&#xD;
                  4. Has a known additional malignancy that is progressing or requires active&#xD;
                  treatment within the past 5 years.&#xD;
&#xD;
               1. Exceptions include basal cell carcinoma of the skin; squamous cell carcinoma of&#xD;
                  the skin that has undergone potentially curative surgery; in situ cervical&#xD;
                  cancer; early stage of prostate cancer (stage 1) with low Gleason score â‰¤6; and&#xD;
                  prostate-specific antigen (PSA) undetectable.&#xD;
&#xD;
               2. A history of urothelial carcinoma, including upper tract urothelial carcinoma or&#xD;
                  bladder cancer who received curative-intent surgery (nephroureterectomy,&#xD;
                  segmentectomy, TURBT, partial cystectomy, radical cystoprostectomy) &gt; 12 months&#xD;
                  before first-dose trial treatment will be the exception.&#xD;
&#xD;
                  5. Has a history of (non-infectious) pneumonitis or interstitial lung disease or&#xD;
                  pulmonary fibrosis diagnosed based on imaging (CT of chest preferably).&#xD;
&#xD;
                  6. Has active tuberculosis (TB) (Bacillus tuberculosis). 7. Has an active&#xD;
                  infection requiring systemic therapy within 7 days prior to the first dose of&#xD;
                  trial treatment.&#xD;
&#xD;
                  8. Is pregnant or breastfeeding, or expecting to conceive or father children&#xD;
                  within the projected duration of the trial, starting with the screening visit&#xD;
                  through 5 months or more after the last dose of nivolumab.&#xD;
&#xD;
                  9. Has a history of uncontrolled or significant cardiovascular disease meeting&#xD;
                  any of the following:&#xD;
&#xD;
               1. Myocardial infarction within 180 days before first-dose of trial treatment&#xD;
&#xD;
               2. New York Heart Association (NYHA) class III or IV congestive heart failure&#xD;
&#xD;
               3. Myocarditis, no matter what etiology should be excluded&#xD;
&#xD;
               4. Arrhythmia requiring treatment (e.g. atrial fibrillation/flutter, ventricular&#xD;
                  tachycardia or fibrillation, paroxysmal supraventricular tachycardia, symptomatic&#xD;
                  bradycardia, sick sinus syndrome or high-grade atrioventricular block).&#xD;
&#xD;
               5. Has permanent pacemaker implantation or implantable cardioverter defibrillator&#xD;
                  (ICD).&#xD;
&#xD;
                  10. Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2&#xD;
                  agent or with an agent directed to another co-inhibitory T-cell receptor (e.g.,&#xD;
                  CTLA-4, OX-40, CD137).&#xD;
&#xD;
                  11. Has undergone major surgery (any surgery involving general anesthesia) within&#xD;
                  28 days before first-dose of study therapy.&#xD;
&#xD;
                  12. Has a known history of human immunodeficiency virus (HIV) (HIV 1/2&#xD;
                  antibodies).&#xD;
&#xD;
                  13. Has known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV&#xD;
                  RNA [qualitative] is detected). Controlled (treated) hepatitis B subject will be&#xD;
                  allowed if they meet the following criteria:&#xD;
&#xD;
               1. Antiviral therapy for HBV must be given for at least 8 weeks and HBV viral load&#xD;
                  must be less than 100 IU/mL prior to first dose of study drug.&#xD;
&#xD;
               2. Subject who are anti-HBc (+), negative for HBsAg, negative for anti-HBs and have&#xD;
                  an HBV viral load under 100 IU/mL don't need HBV anti-viral prophylaxis.&#xD;
&#xD;
                  14. Has received a live virus vaccine within 30 days of planned start of trial&#xD;
                  therapy.&#xD;
&#xD;
                  15. Has known CNS metastases and/or leptomeningeal carcinomatosis. 16. Has&#xD;
                  symptomatic ascites or pleural effusion. 17. Has had a prior allogeneic stem cell&#xD;
                  or bone marrow transplant. 18. Has received any unapproved or unlicensed drug&#xD;
                  (e.g. marketed drugs unapproved for urothelial carcinoma, investigational use of&#xD;
                  drugs, herb combination) within 28 days before first-dose of study drug.&#xD;
&#xD;
                  19. Are otherwise unfit for the study in the investigator's or sub-investigator's&#xD;
                  opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Li Su, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Li Su, MD</last_name>
    <phone>+886-975056834</phone>
    <email>yolisu@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chien-Ya Lin, RPN</last_name>
    <phone>+886-7-7317123</phone>
    <phone_ext>3681</phone_ext>
    <email>chanyai0725@cgmh.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Li Su, MD</last_name>
      <phone>+886-975056834</phone>
      <email>yolisu@cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chien-Ya Lin, RPN</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>3681</phone_ext>
      <email>chanyai0725@cgmh.org.tw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>YULISU</investigator_full_name>
    <investigator_title>Assistant Professor-level Attending Physician</investigator_title>
  </responsible_party>
  <keyword>upper tract urothelial carcinoma</keyword>
  <keyword>immune checkpoint inhibitor</keyword>
  <keyword>neoadjuvant treatment</keyword>
  <keyword>pathological complete response</keyword>
  <keyword>whole exome sequencing</keyword>
  <keyword>biomarker</keyword>
  <keyword>RNA sequencing</keyword>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

